Anixa Biosciences Inc (ANIX)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
The company declared operating shortfall in the first quarter of 2023
company announced first quarter of 2023 operating deficit of $-2.556 millions
Published Mar 27 2023
CSIMarket Team / CSIMarket.com
The shareholders haven't anticipated any adjustments at the business during the the earnings cycle of fiscal November to January 31 2023 at the company. Yet, stockholders monitor ANIXs' operating shortfall which has been at $-2.556 millions, during the matching time.
Such numbers represent an improvement from those the first quarter of 2022, where the operating shortfall has been at $-3.88 millions, this is just one of major signs for the situation at the company. Because evolving corporations like the ANIX, still build up the respective revenue streams, it's crucial for the businesses to run efficiently, to attain the next level.
Because the company is still growing the revenue streams, somehow ANIX has managed to curb the deficit in the financial first quarter of 2023 to $-2.354 millions, from the $-3.879 millions, in the first quarter of 2022.
Anixa Biosciences Inc is expected to report next financial recent numbers on June 09, 2023.
Such numbers represent an improvement from those the first quarter of 2022, where the operating shortfall has been at $-3.88 millions, this is just one of major signs for the situation at the company. Because evolving corporations like the ANIX, still build up the respective revenue streams, it's crucial for the businesses to run efficiently, to attain the next level.
Because the company is still growing the revenue streams, somehow ANIX has managed to curb the deficit in the financial first quarter of 2023 to $-2.354 millions, from the $-3.879 millions, in the first quarter of 2022.
Anixa Biosciences Inc is expected to report next financial recent numbers on June 09, 2023.